Acambis researching single-shot solution to flu

Shares of the UK's Acambis surged this morning as the drug developer announced it would soon begin human trials on a new flu vaccine that could potentially offer permanent protection against all types of flu. Investors were cheered by the prospect that a successful set of trials could offer global protection against the flu, which each year requires huge sums and massive shipments of drugs that may have no effect on whatever strain of the flu is making the rounds. In addition, Acambis said that the experimental vaccine would potentially protect against a global flu pandemic. A universal flu vaccine from Acambis would also have a negative effect on companies like Chiron, which have invested large sums in the flu vaccine business.

- read this story from The Daily Mail for more

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.